SCHEMBL22750107

SCHEMBL22750107

NCCCC[C@H](NC(=O)[C@@H](N)CCCCN)C(=O)NCCCCCC(=O)OCc1ccccc1

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SIRT2 Q8IXJ6 10/20 0.62
SIRT1 Q96EB6 8/20 0.62
SIRT3 Q9NTG7 8/20 0.62
MEN1 O00255 1/20 0.58
ALDH1A1 P00352 1/20 0.58
HPGD P15428 1/20 0.58
KMT2A Q03164 1/20 0.58
CPB1 P15086 1/20 0.57
CPB2 Q96IY4 1/20 0.57
TLR2 O60603 1/20 0.52
PTGER4 P35408 3/20 0.51
MMP2 P08253 1/20 0.49
ANPEP P15144 1/20 0.48
CHRNA1 P02708 1/20 0.48
CHRNG P07510 1/20 0.48
CHRNB1 P11230 1/20 0.48
CHRND Q07001 1/20 0.48
LTA4H P09960 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16217772 1.00 SIRT2 (0.62) SIRT2SIRT1SIRT3MEN1ALDH1A1
SCHEMBL18972974 0.95 SIRT2 (0.70) SIRT2SIRT1SIRT3MEN1ALDH1A1
SCHEMBL16217828 0.92 SIRT2 (0.55) SIRT2SIRT1SIRT3MEN1ALDH1A1
SCHEMBL19871881 0.92 SIRT2 (0.55) SIRT2SIRT1SIRT3MEN1ALDH1A1
SCHEMBL19062407 0.91 MEN1 (0.71) SIRT2SIRT1SIRT3MEN1ALDH1A1
SCHEMBL18791194 0.90 CPB1 (0.57) SIRT2SIRT1SIRT3MEN1ALDH1A1
SCHEMBL30891387 0.90 SIRT2 (0.75) SIRT2SIRT1SIRT3MEN1ALDH1A1
SCHEMBL19156039 0.89 SIRT2 (0.53) SIRT2SIRT1SIRT3MEN1ALDH1A1
SCHEMBL24234674 0.87 MMP2 (0.54) SIRT2SIRT1SIRT3MEN1ALDH1A1
SCHEMBL12202911 0.86 MEN1 (0.68) SIRT2SIRT1SIRT3MEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12427187-B2 Glucose-responsive insulin conjugates MERCK SHARP & DOHME LLC (US) 2025-09-30 US disclosed
US-20220233647-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES MERCK SHARP & DOHME CORP. (US) 2022-07-28 US disclosed
EP-3980052-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES MERCK SHARP & DOHME CORP. (US) 2022-04-13 EP disclosed
WO-2020247297-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES MERCK SHARP & DOHME CORP. (US) 2020-12-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12427187-B2 Glucose-responsive insulin conjugates GPR119, IRS1, INSR SIRT2 3319/4885SIRT1 1862/4885SIRT3 3516/4885
US-20220233647-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES GPR119, IRS1, INSR SIRT2 3319/4885SIRT1 1862/4885SIRT3 3516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.